1. Thomson CA, Stopeck AT, Bea JW, Cussler E, Nardi E, Frey G, Thompson PA. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutr Cancer. 2010;62(8):1142-52.
2. Thompson PA, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res (Phila). 2010 Jan;3(1):101-7.
3. Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT. Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach. Presented at the Society of Photo-Optical Instrumentation Engineers, (Meeting Proceedings 2010 Feb 27;7627. pii: 76270L (2010).
4. Stopeck A. Denosumab findings in metastatic breast cancer. Clin Adv Hematol Oncol. 2010 Mar;8(3):159-60.
5. Jha AK, Rodríguez JJ, Stephen RM, Stopeck AT. A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images. Presented at the IEEE Southwest Symposium on Image Analysis & Interpretation, Tucson, AZ, May 2010.
6. Chalasani P, Downey L, Stopeck AT. Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med. 2010 Jun;123(6):489-95.
7. T. Trouard, P. Thompson, C. Huang, M. Altbach, M. Kupinski, D. Roe, K.Fitzpatrick, P. Granstrom, G. Frey, S. Squire, V. Poulin, and A. Stopeck. Fat water ratio and diffusion-weighted MRI applied to the measure of breast density as a cancer risk biomarker. Proceeding of the International Society for Magnetic Resonance in Medicine, 2010, Stockholm, Sweden, May 2010.
8. A Lipton, A Stopeck, R von Moos, DH Henry, GE Richardson; A Meta-analysis of Results From Two Randomized, Double-blind Studies of Denosumab Versus Zoledronic Acid (ZA) For Treatment of Bone Metastases; Oral Presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June, 2010.
9. Stopeck A, de Boer R, Fujiwara Y, Tonkin K, Yardley D. Denosumab vs Zoledronic Acid for the Treatment of Bone Metastases: Skeletal-Related Events in a Meta-analysis from Two Randomised, Double-blind Studies; Presented at Multinational Association of Supportive Care in Cancer 2010 International Symposium in Vancouver, BC, June 26, 2010.
10. Jha AK, Kupinski MA, Rodriguez JJ, Stephen RM, Stopeck AT. "ADC Estimation of Lesions in Diffusion-Weighted MR Images: A Maximum-Likelihood Approach", Poster presentation at 2010 IEEE Southwest Symposium on Image Analysis and Interpretation, Tucson, AZ, May 2010.
11. **M Iannone, L Pennick, M Damiano, K Weihs, A Ratts, A Stopeck. “Prevalence of Depression in Adults with Hemophilia”, XXIX International Congress of the World Federation of Hemophilia, July 2010 Buenos Aires, Argentina.
12. Brown JE, Barrios CH, Diel JJ, Facon T, Fizazi K, Ibrahim T, Saad F, Senecal F, Stemmer SM, Stopeck A, Takahashi S, Van Poznak C, Zhou L, Carriere P, Daniels A, Dansey R. Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for the treatment of bone metastases in advanced cancer patients or myeloma. Presented at the 10th International Conference of Cancer-Induced Bone Disease (CIBD). Sheffield, UK, September, 2010.
13. **A Stopeck. Health Resource Utilization of Subjects Receiving Denosumab and Zoledronic Acid in a Randomized Phase 3 Trial of Advanced Breast Cancer Patients with Bone Metastases. ISPOR 13th Annual European Congress 2010
14. Stopeck A, Lipton AA, Campbell-Baird C, von Moos R, Fan M, Haddock B, Braun A. Acute-Phase Reactions Following Treatment With Zoledronic Acid or Denosumab: Results From a Randomized, Controlled Phase 3 Study in Patients With Breast Cancer and Bone Metastases Poster presentation at the 33rd Annual San Antonio Breast Cancer Sysmposium, San Antonio, December, 2010.
15. Stopeck A, Martin M, Ritchie D, Body JJ, Paterson A, Viniegra M, Jassem J,Takano T, Van Poznak C, Bourgeois H, Fan M, Dansey R, Braun A. Effect of Denosumab Versus Zoledronic Acid Treatment In Patients With Breast Cancer and Bone Metastases: Results From The Extended Blinded Treatment Phase. Poster presentation at the 33rd Annual San Antonio Breast Cancer Sysmposium, San Antonio, December, 2010.
16. Stopeck A, Fallowfield L, Patrick D, Cleeland C, de Boer R, Steger GG, Qian Y, Braun A, Dansey R, Chung K. Pain Outcomes in Patients With Metastatic Breast Cancer: Results From a Phase 3 Trial of Denosumab vs Zoledronic Acid. Poster presentation at the American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, September, 2010.
17. JJ Body, R von Moos, A Stopeck, Y Qian, A Braun, K Chung. Health Resource Utilization of Subjects Receiving Denosumab and Zoledronic Acid in a Randomized Phase 3 Trial of Advanced Breast Cancer Patients With Bone Metastases. Presented at the International Society for Pharmacoeconomics and Outcomes Research European Congress, Prague, Czech, November, 2010.
18. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10;28(35):5132-9.
19. Brown-Glaberman U, Graham A, Stopeck A. A case of metaplastic carcinoma of the breast responsive to chemotherapy with ifosfamide and etoposide: improved antitumor response by targeting sarcomatous features. Breast J. 2010 Noc-Dec;16(6):663-5.
20. Greenberg S, Stopeck A, Rugo HS. Systemic treatment of early breast cancer--a biological perspective. J Surg Oncol. 2011 May 1;103(6):619-26
21. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011 Jun 20;29(18):2459-65.
22. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011 Aug 1;17(15):5132-9.
23. Gralow JR, Lipton A, Stopeck AT. How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer? J Clin Oncol. 2011 Sep 10;29(26):3591-2.
24. A Lipton, K Fizazi, A Stopeck, D Henry, J Brown, F Saad, D Yardley, P Maroto, C Ke, S Jun. “Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid: Combined Analysis From 3 Registrational Trials”, Presented at the European Society of Medical Oncology Annual meeting, Stockholm, Sweden, September, 2011
25. JJ Diel, JJacques Body, A Stopeck, S Vadhan-Raj, A Spencer, G Steger, R von Moos, F Goldwasser, M Fan, A Braun. “Effect of Denosumab Treatment on Prevention of Hypercalcemia of Malignancy in Cancer Patients with Metastatic Bone Disease, Presented at the European Society of Medical Oncology Annual meeting, Stockholm, Sweden, September, 2011.
26. G Richardson, S Siena, A Lipton, J Brown, A Stopeck, K Fizazi, D Henry, F Saad, C Ke, A Braun. Comparison of denosumab versus zoledronic acid (ZA) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Oral presentation at the Clinical Oncological Society of Australia meeting, Perth, Australia, November, 2011.
27. **S Siena, G Richardson , A Lipton, J Brown, A Stopeck, K Fizazi, D Henry, F Saad, C Ke, A Braun. Prevention of skeletal-related events in patients with bone metastases from solid tumors: Comparison of denosumab versus zoledronic acid (ZA) in a combined analysis of 3 registrational trials. Poster presentation at ECCO/ESMO 2011
28. *A Stopeck. Effect of Denosumab Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Open-label Extension Treatment Phase. Poster presentation at SABCS 2011.
29. R de Boer, M Martin, GG Steger, R von Moos, A Stopeck, K Tonkin, G Rodriguez, M Viniegra, H Bourgeois, K Inoue, B Ding, K Chung, A Braun. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases: a number-needed-to-treat analysis. Poster presentation at the Medical Oncology Group of Australia meeting, Adelaide, Australia, August, 2011.
30. * A Stopeck. Pain Severity Associated with SRE for SABCS. Poster presentation –SABCS 2011
31. M Martin, G Steger, R von Moos, A Stopeck, R de Boer, K Tonkin, G Rodriguez, MViniegra, H Bourgeois, K Inoue, B Ding, K Chung, A Braun. Benefit of Denosumab Therapy in Patients with Bone Metastases from Breast Cancer: a Number-Needed-to-Treat (NNT) Analysis. Presented at the 12th International St Gallen Breast Cancer Conference, St. Gallen, Switzerland, March, 2011.
32. R Stephen, D Roe1, A Jha, H Cui, S Squire, G Frey, T Trouard, J Galons, J Rodriquez, M Kupinski, E Outwater, R Gillies, A Stopeck. Diffusion-Weighted MRI of the Liver: Parameters of Acquisition and Analysis and Predictors of Chemotherapy Response. Poster presentation at the International Society for Magnetic Resonance Imaging in Medicine, Montreal, Canada, May, 2011.
33. Gerber DR, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011 Nov 1;17(21):6888-96.
34. P Chalasani, U Brown-Glaberman, MC Kissee, ML Damiano, R Nagle, AT Stopeck. Synovial Inflammation and Osteoporosis Development in Adult Hemophilia Patients. Presented at the Annual HTRS meeting, Chicago, IL April, 2011.
35. Rugo HS, Jo Chien A, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011 Dec 24.
36. Stopeck AT, Lipton A, Martín M, Body J-J, Paterson A, Steger GG, Tonkin K, de Boer RH, Fujiwara Y, Yardley D, Jassem J, Takano T, Solal-Celigny P, Fan M, Braun A. Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study. Poster presentation at 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2011.
37. Fallowfield L, Cleeland CS, Body J-J, Stopeck A, von Moos R, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, De Boer R, Salvagni S, Tosello Oliveira C, Ying W, Braun A, Cong Z. Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases. Poster presentation at 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2011
38. M Marron, A Stopeck. Microparticle generation and activation after treatment with paclitaxel and bavituximab combination therapy in metastatic breast cancer. Poster presentation at the Annual meeting of the American Association for Cancer Research, Chicago, IL, April, 2012.
39. K Chung, A Stopeck, M Danese, Z Cong, M Halperin, Y Qian, A Braun. Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-Related Events (SREs) in Patients with Breast Cancer and Bone Metastases (BM). Poster presention at the 8th Annual Hematology/Oncology Pharmacy Association conference, Salt Lake City, Utah, March, 2012.
40. LS Matza, Z Cong, K Chung, A Stopeck, K Tonkin, J Brown, A Braun, K Van Brunt, K McDaniel. Health State Preferences Associated with Subcutaneous Injections and Intravenous Infusions for Treatment of Bone Metastases. Poster presentation at the Annual meeting of the American Society of Clinical Oncology, Chicago, IL, June, 2012.
41. R de Boer, M Martin, GG Steger, R von Moos, A Stopeck, K Tonkin, G Rodriguez, H Bourgeois, K Inoue, B Ding, K Chung, A Braun. A number-needed-to-treat analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases. Poster presentation at the International Symposium on Oncology Pharmacy Practice, Melbourne, Australia, May, 2012.
42. Ursa Brown-Glaberman, Alison T Stopeck. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics: targets & therapy, 2012; 6: 89-99
43. AT Stopeck, A Lipton, M Martín, JJ Body, A Paterson, GG Steger, K Tonkin, R de Boer, Y Fujiwara, D Yardley, J Jassem, T Takano, P Solal-Celigny, M Fan, A Braun. Results From the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study of Denosumab in Patients with Breast Cancer and Bone metastases Previously Treated with Zoledronic Acid or Denosumab. Oral Presentation at the Asian Oncology Summit, Singapore, April 2012.
44. AT Stopeck, G Richardson, S Siena, A Lipton, J Brown, K Fizazi, D Henry, F Saad, C Ke, A Braun. Denosumab versus zoledronic acid for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM) secondary to solid tumours: an integrated analysis of three phase 3 studies. Poster presentation at the Asian Oncology Summit, Singapore, April 2012.
45. F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carriáere; R Dansey. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases 3. Ann Oncology, 23, no. 5 (2012): 1341-1347.
46. Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with dolid tumors and bone metastases in the United States. J Med Econ. 2012 Mar 27.
47. Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K, Stopeck AT. Prevalence of depression in adults with haemophilia. Haemophilia. 2012 May 30.
48. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012 Jun 13.
E-mail this page